Influence of aggregation and route of injection on the biodistribution of mouse serum albumin

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Kijanka, Grzegorz ^a   Prokopowicz, Malgorzata ^a   Schellekens, Huub ^a,b   Brinks, Vera ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FLUORESCENT DYE; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; EX VIVO STUDY; FEMALE; FLUORESCENCE; IN VIVO STUDY; LIVER; LUNG; LYMPHATIC SYSTEM; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; SPLEEN; ANIMAL; CHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUMINESCENCE; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ANIMALS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FLUORESCENT DYES; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LIVER; LUMINESCENT MEASUREMENTS; LUNG; MICE; SERUM ALBUMIN; SPLEEN; TISSUE DISTRIBUTION;

EID: 84899835845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085281     Document Type: Article

References (22)

1. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, et al. (2000) Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48: 95-100 (Pubitemid 30608666)
2. Schellekens H, Casadevall N (2004) Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251: II4-9
3. Singh SK (2011) Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100: 4-16
4. Moore WV, Leppert P (1980) Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51: 691-697 (Pubitemid 10024715)
5. Braun A, Kwee L, Labow MA, Alsenz J (1997) Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14: 1472-1478 (Pubitemid 27481082)
6. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, et al. (2006) Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95: 1084-1096 (Pubitemid 43723167)
7. van Beers MMC, Jiskoot W, Schellekens H (2010) On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res 30: 767-775
8. Filipe V, Hawe A, Schellekens H, Jiskoot W (2010) Aggregation and immunogenicity of therapeutic proteins. In Wang W, Roberts CJ editors. Aggregation of therapeutic proteins, Hoboken NJ: John Wiley & Sons, Inc. p 403-433
9. Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8: E501-507
10. Filipe V, Poole R, Oladunjoye O, Braeckmans K, Jiskoot W (2012) Detection and characterization of subvisible aggregates of monoclonal IgG in serum. Pharm Res 29: 2202-2212
11. Kijanka G, Jiskoot W, Schellekens H, Brinks V (2013) Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice. Pharm Res 30: 1553-1560
12. Peng A, Kosloski MP, Nakamura G, Ding H, Balu-Iyer SV (2012) PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. AAPS J 14: 35-42
13. Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, et al. (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48: 706-712
14. Schellekens H (2005) Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20 Suppl 6: vi3-9
15. Srinivas NR, Shyu WC, Weiner RS, Warner G, Comereski C, et al. (1997) Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Pharm Res 14: 911-916 (Pubitemid 27326987)
16. Laursen T, Møller J, Jørgensen JO, Orskov H, Christiansen JS (1996) Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. Clin endocrinol 45: 333-339 (Pubitemid 26306702)
17. Porter CJ, Edwards GA, Charman SA (2001) Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev 50: 157-171 (Pubitemid 32727281)
18. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743
19. Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, et al. (2011) Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol imaging 11: 33-46
20. Administration. FaD. Adalimumab (2002) Pharmacology reviews: Adalimumab product approval information - licensing action.; 2002 December 31. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2008/125057s110TOC.cfm
21. Ockner RK, Weisiger RA, Gollan JL (1983) Hepatic uptake of albumin-bound substances: albumin receptor concept. Am J Physiol. 245: G13-18 (Pubitemid 14227197)
22. Brunskill NJ (2004) Albumin receptors - structure and function. In: Duttaroy AK, Spener F. editors. Cellular proteins and their fatty acids in health and disease. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA, p 79-94